SAE's guide for automakers and charging companies to integrate NACS chargers reveals how superior it is to what everyone else ...

So, for the 2026 model year, the carmaker has given the Polestar 3 crossover a much-appreciated revamp under the skin, swapping in an new 800-volt electrical architecture. The new more powerful system ...

Despite debuting for the 2025 model year, the Polestar 3 is significantly upgraded for 2026. Most notably, the electric compact luxury SUV switches from a 400-volt platform to an 800-volt setup, which ...

Arthrosi Therapeutics has raised $153 million to bankroll its bid to clout gout. The series E financing gives the biotech the financial firepower to deliver data from two phase 3 trials next year. San ...

Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Compared with Standard Therapy Alone Repatha is Now the First and Only ...

Roche has posted a mixed set of data from two clinical trials of its anti-IL-33/ST2 antibody astegolimab in chronic obstructive pulmonary disease (COPD), casting a shadow over the programme. On the ...

Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

MoonLake Immunotherapeutics’ stock has taken a pummeling after the biotech blamed an unexpectedly high placebo response rate for its much-hyped inflammatory disease prospect missing the key goal of ...

Cidara Therapeutics has kicked off its Phase 3 trial for CD388, an influenza preventative, after receiving a green light from the FDA to accelerate and broaden enrollment to new high-risk groups, ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Killing Floor 3 is back with a bang, adding new weapons, updated attachments, and a reworked perk ...

Roche's Hemlibra treatment for haemophilia A is one of its top-selling drugs, making almost $5 billion last year, and the company has now lined up what looks like an impressive successor. The pharma ...

- Orelabrutinib, a highly selective CNS-penetrant, oral small molecule Bruton’s Tyrosine Kinase (BTK) inhibitor with best-in-class potential now in Phase 3 development for progressive forms of ...